Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The recent policy issued by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical and biotechnology index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.1 percentage points [11] - The report suggests focusing on high-quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin, as the pharmaceutical commercial sector is expected to see improved performance due to favorable policies [33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Among sub-sectors, pharmaceutical commerce rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] - The top five A-share stocks in the industry this week included *ST Changyao (+70.37%) and Hualan Biological Engineering (+32.21%) [22] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and industry structure [28] - A loan interest subsidy policy for small and micro enterprises in the pharmaceutical sector was announced, aimed at encouraging investment in manufacturing [28] Company Announcements - Significant announcements include the resignation of executives at various companies and performance forecasts indicating potential losses for some firms due to price reductions and demand declines [36]

Core Viewpoint - The implementation of the new National Medical Insurance Drug List and the Commercial Insurance Innovative Drug List on January 1, 2026, marks a significant enhancement in drug accessibility for patients, with 114 new drugs added to the national list and 19 to the commercial list, optimizing medication security for the public [1][3][4]. Summary by Sections National Medical Insurance Drug List - The new National Medical Insurance Drug List includes 114 new drugs, with 50 classified as innovative drugs, representing the highest number and proportion of innovative drugs added in history [4][15]. - The newly added drugs aim to fill clinical treatment gaps, offer superior alternatives, or provide better cost-effectiveness, particularly enhancing coverage for cancer, chronic diseases, mental health, rare diseases, and pediatric medications [4][15]. Commercial Insurance Innovative Drug List - The first version of the Commercial Insurance Innovative Drug List includes 19 drugs, focusing on high innovation, significant clinical value, and patient benefits that exceed basic insurance coverage [5][16]. - The list features treatments for conditions such as cancer (e.g., CAR-T therapies), rare diseases (e.g., neuroblastoma, Gaucher disease), and Alzheimer's disease, reflecting a commitment to support innovative therapies [5][16]. Implementation and Accessibility - As of January 20, 2026, 99 new drugs from the basic medical insurance list are available in 12,198 designated medical institutions, while 14 drugs from the commercial list are available in 223 institutions [7][19]. - Local medical insurance departments are actively ensuring the supply and settlement of new drugs, with measures such as updating drug databases and holding specialized drug meetings to facilitate the integration of new drugs into hospital procurement lists [19][20]. Public Access and Information - The public can access information about the drugs included in the new lists through the "National Medical Insurance Bureau" WeChat account, allowing users to search for drug names and check their status in the directories [17]. Future Directions - The implementation of the dual directories (national and commercial) is expected to enhance the efficiency of medical insurance fund usage and improve public medication security, with ongoing adjustments to ensure that essential and effective new drugs are included while removing outdated ones [11][24][25].

Core Insights - The new basic medical insurance drug list has been officially implemented since January 1, 2026, with many insured individuals already purchasing newly added drugs from medical institutions [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the basic medical insurance drug list, with over half of these drugs already recorded in sales at medical institutions [1] - The drug Tirzepatide injection, used for treating adult type 2 diabetes, has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug Icosapent ethyl injection, which is administered once every six months, has been recorded in sales at 400 medical institutions [1] Group 2: Access and Information - Insured individuals can check the availability of insured drugs at medical institutions through the "National Medical Insurance Negotiated Drug Supply Institution List Inquiry" on the National Medical Insurance Service Platform [1]

Core Insights - The report emphasizes the importance of longevity medicine, which focuses on proactive health and disease prevention, as a critical response to the aging population and the challenges of "pathological longevity" [2][9][14] - The aging population in China is rapidly increasing, with the number of individuals aged 65 and above reaching 203 million in 2023, accounting for 25% of the global elderly population [10] - The demand for longevity medicine is accelerating, driven by the need for aging management, early prevention, and comprehensive health optimization, transitioning the healthcare model from disease treatment to continuous management [2][11][14] Industry Overview - The longevity medicine industry in China is still in its early stages, characterized by a dual-track development model where public institutions focus on research foundations while private entities explore service and business models [11] - The industry is facing structural pressures due to the increasing burden of chronic diseases and the inefficiencies of the traditional disease-centered healthcare system [2][10] - The report highlights that the core competitive advantage in the industry will shift towards long-term health management capabilities, data integration, and value proposition [11] Market Performance - The pharmaceutical sector showed positive performance in the week of January 5-9, 2026, with all six sub-sectors recording gains, particularly in medical services (+12.34%) and medical devices (+9.42%) [15] - The report notes that the valuation levels for biopharmaceuticals and chemical pharmaceuticals are among the highest, at 89.93 times and 84.19 times respectively [15] Innovations and Developments - A significant breakthrough in cancer vaccine research was reported by a team from Peking University, utilizing protein-targeted degradation technology to enhance immune response against cancer cells [22][25] - The new basic medical insurance drug list was implemented on January 1, 2026, with over half of the newly added 114 drugs already available in medical institutions [26] - The National Medical Products Administration is enhancing support for innovative drugs, aiming for a significant increase in the approval of new drugs and medical devices in 2025 [27][30][31]

Core Insights - The new basic medical insurance drug catalog has officially been implemented as of January 1, 2026, with 114 new drugs added [1] - Over half of the newly included drugs have recorded sales in medical institutions within the first week of implementation [1] Group 1: Drug Sales and Availability - The drug teriparatide injection for treating adult type 2 diabetes has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug inclisiran injection, known for its semi-annual dosing, has been sold in 400 medical institutions [1] Group 2: Access to Information - Insured individuals can check the availability of insurance-covered drugs in medical institutions through the National Medical Insurance Service Platform [1]

Core Insights - The new basic medical insurance drug list has been officially implemented since January 1, 2026, with many insured individuals already purchasing newly added drugs from medical institutions [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the basic medical insurance drug list, with over half of these drugs already recorded in sales at medical institutions [1] - The drug Tirzepatide injection, used for treating adult type 2 diabetes, has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug Icosapent ethyl injection, known for its "half-yearly injection" regimen, has been recorded in sales at 400 medical institutions [1] Group 2: Access and Information - Insured individuals can check the availability of insured drugs at medical institutions through the "National Medical Insurance Negotiated Drug Supply Institution List" on the National Medical Insurance Service Platform [1]

Core Viewpoint - Company has received approval from the National Medical Products Administration for clinical trials of HRS9531 and HRS-5817 injection solutions, which are expected to enhance its product pipeline in the obesity treatment market [1][2] Group 1: HRS9531 Injection - HRS9531 is a novel dual agonist targeting GLP-1R and GIPR, designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding weight loss [1] - The global sales forecast for ZEPBOUND, a similar drug by Eli Lilly, is approximately $4.926 billion for 2024, indicating a significant market opportunity for HRS9531 [1] - Cumulative R&D investment for HRS9531 has reached approximately 51.854 million yuan [1] Group 2: HRS-5817 Injection - HRS-5817 is a self-developed Class 1 chemical drug, showing weight loss effects in preclinical studies on obese animal models with good safety profiles [2] - Currently, there are no approved drugs targeting the same receptor as HRS-5817 in both domestic and international markets, highlighting its potential uniqueness [2] - Cumulative R&D investment for HRS-5817 has reached approximately 2.489 million yuan [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS9531 and HRS-5817 injection solutions, indicating progress in their drug development pipeline [1][2] Group 1: HRS9531 Injection - HRS9531 injection is a novel dual agonist targeting GLP-1R and GIPR, aimed at regulating glucose and lipid metabolism, suppressing appetite, and enhancing insulin sensitivity, which can improve blood sugar levels and aid in weight loss [1] - The only other drug targeting the same indications globally is Eli Lilly's Zepbound, which is expected to generate approximately $4.926 billion in global sales in 2024 [1] - The total R&D investment for the HRS9531 project has reached approximately 51.854 million yuan [1] Group 2: HRS-5817 Injection - HRS-5817 injection is a self-developed Class 1 chemical drug, showing weight loss effects in preclinical studies on obese animal models with good safety profiles [2] - Currently, there are no approved drugs targeting the same receptor as HRS-5817 in both domestic and international markets [2] - The cumulative R&D investment for HRS-5817 injection has reached approximately 2.489 million yuan [2]